Preclinical Evidence is a recurring topic in our peptide coverage. This hub collects every article tagged Preclinical Evidence, newest first, each evidence-graded and tied to real, verifiable sources.
An evidence-graded review of the peptides marketed for ankle sprains, ATFL tears and Achilles injury. The honest 2026 verdict: no human RCT exists; the strongest case is preclinical (rat Achilles models), and PRP — not a peptide — has the better human ankle evidence.
A clinical-editorial breakdown of the peptides marketed for 'adrenal fatigue,' stress and burnout — starting from the fact that 'adrenal fatigue' is not a recognized diagnosis, then grading Selank, DSIP and thymosin alpha-1 honestly against human, animal and absent evidence.
A clinical monograph on zinc-thymulin — the zinc-dependent thymic nonapeptide marketed as a topical hair-growth peptide. One small open-label human trial, solid zinc-biomarker biology, no RCT, and an unsettled 2026 legal status.
A clinical monograph on Vilon — the synthetic Lys-Glu dipeptide bioregulator marketed for immune and longevity support. Rodent and in-vitro signals only, no human RCT, and no legal compounding pathway in 2026.
A clinical monograph on thymulin — the zinc-dependent thymic nonapeptide (facteur thymique serique). Real T-cell biology, two small 1980s rheumatoid-arthritis RCTs, otherwise preclinical, and an unsettled 2026 legal status.
A clinical monograph on Ac-SDKP (goralatide/seraspenide), the N-terminal tetrapeptide fragment of thymosin beta-4. Human chemoprotection data (Grade B), preclinical-only anti-fibrosis, and a WADA-prohibited 2026 status.
A clinical monograph on TB-500 — the synthetic thymosin β4 fragment (Ac-LKKTETQ) marketed for tendon, muscle and tissue repair. Strong preclinical biology, no human efficacy RCT of the fragment, and an unsettled 2026 legal status.
A clinical monograph on SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate, Tripeptide-3) — the snake-venom-mimetic 'Botox-in-a-jar' topical peptide. Strong in-vitro receptor data, modest sponsor-run human data, and no independent RCT of the isolated peptide.
A clinical monograph on SNAP-8 (Acetyl Octapeptide-3) — the topical "needle-free Botox" cosmetic peptide. An elongated Argireline with a plausible SNARE-competing mechanism, but only manufacturer claims and one combination-product human trial behind it.
A clinical monograph on SLU-PP-332 — the synthetic pan-ERR agonist sold as an 'exercise mimetic.' It is not a peptide, has zero human trials, and is functionally banned in sport.
A clinical monograph on Noopept (omberacetam) — the proline-glycine dipeptide nootropic and cycloprolylglycine prodrug. Small Russian human trials in cognitive impairment, a deep preclinical mechanism, and an unsettled 2026 legal status.
A clinical monograph on PTD-DBM — the CXXC5-Dishevelled disrupting peptide engineered to reactivate Wnt/β-catenin signaling for hair regrowth. Strong target biology, mouse-only efficacy, and no human trials.
A clinical monograph on Prostamax — the synthetic prostate-tropic tetrapeptide Lys-Glu-Asp-Pro (KEDP) from the Khavinson school. The human prostate evidence belongs to the parent bovine-prostate extract, not the synthetic peptide.
A clinical monograph on Pentadeca Arginate (PDA) — the L-arginine salt of BPC-157 marketed for tendon, gut and wound healing. Zero PDA-specific studies, borrowed preclinical data, and an unsettled 2026 legal status.
A clinical monograph on Pentadeca Arginate — the L-arginine salt of BPC-157. No studies exist under the 'PDA' name; the borrowed parent evidence is 35:1 preclinical, with zero human RCTs and an unsettled 2026 legal status.
A clinical monograph on PEG-MGF — the pegylated Mechano Growth Factor E-peptide marketed for muscle repair and recovery. Preclinical-only evidence, no human trials, and a restricted 2026 legal status.
A clinical monograph on P21 (P021, Ac-DGGLAG-NH2) — a small-molecule CNTF mimetic marketed as a nootropic peptide. Reproducible rodent neurogenesis and anti-tau data, but zero human trials and an unapproved-research-chemical status.
A clinical monograph on N-Acetyl Selank Amidate — a twice-stabilized analog of the Russian anxiolytic peptide Selank. No dedicated human or animal study exists; every claim is extrapolated, placing the analog itself at evidence grade D.
A clinical monograph on the mitochondrial-derived peptide (MDP) axis — MOTS-c, humanin and the small humanin-like peptides (SHLP). One coherent mechanism, three very different maturity tiers, and zero approved human therapies.
A clinical monograph on MOTS-c — the 16-amino-acid mitochondrial-derived peptide marketed as an 'exercise mimetic' and metabolic regulator. Striking rodent data, no completed human efficacy trial, and an unsettled 2026 legal status.
Preclinical Evidence is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Preclinical Evidence, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.